Luke Miels appointed CEO designate for GSK
LONDON: GSK plc (LSE/NYSE: GSK) today announced that Luke Miels is appointed CEO Designate, GSK. He will assume full responsibilities as CEO and join the Board on 1st January 2026. Luke joined GSK in 2017 and is currently Chief Commercial Officer, with world-wide responsibility for medicines and vaccines1. He has been instrumental in building GSK’s…